Navigation Links
New Data Suggests Progression of Disability at Two Years Predicts Multiple Sclerosis (MS) Disability Progression at Eight Years
Date:10/12/2007

Treatment with AVONEX(R) (Interferon Beta-1a) for Two Years Reduces Probability of Reaching More Severe Disability Milestones at Eight Years

PRAGUE, Czech Republic, Oct. 12 /PRNewswire/ -- A post-hoc analysis from a Phase III clinical trial of AVONEX(R) (interferon beta-1a) and post-randomization eight-year follow up shows that six-month sustained progression of disability at two years, using the Expanded Disability Status Scale (EDSS), is a significant predictor of long-term disability, as measured by EDSS milestones of 4.0, 5.0, 6.0 and 7.0 at eight years, in patients with relapsing-remitting multiple sclerosis (RRMS). The analysis suggests that patients taking AVONEX for two years were less likely to experience disability progression over time (eight years) when compared to placebo. These data were announced today at the 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) conference in Prague, Czech Republic.

The analysis involved 160 patients with RRMS who received at least two years of treatment (81 placebo, 79 interferon beta-1a), in the AVONEX Phase III trial and who were re-examined eight years post-randomization. 45 patients met the criteria for two-year disability progression sustained for six months (n=18 AVONEX, 27 placebo). The analysis revealed:

-- Patients initially treated with AVONEX were less likely than patients

initially receiving placebo to progress to EDSS scores of greater than

or equal to 4.0 at eight years

-- Six month sustained EDSS progression during the pivotal two-year trial

was a significant predictor of disability progression eight years later

-- Almost twice as many patients who had sustained progression in EDSS

during the two-year trial progressed to an EDSS of greater than or

equal to 4.0 than patients who did not progress (84% sustained,

versus 44% unsustained)

-- Almost t
'/>"/>

SOURCE AVONEX
Copyright©2007 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3

Related medicine news :

1. Panel suggests selling allergy drugs OTC
2. Study suggests symptom driven therapy for adults with asthma
3. Study Suggests Filtering Out Useless Information To Enhance Memory
4. Women Portray Stronger Immune Response As Compared to Men, Study Suggests
5. Meira Kumar Suggests Monitoring Systems To Check Drug Abuse
6. Genetic Mutation in Mice Suggests Extinct Mammoth Had Light and Dark Fur
7. Study Suggests Links Between Diabetes And Multiple Sclerosis
8. New Research Suggests That Obesity Strikes Faster Growing Kids
9. Valve Disease Study Suggests New Public Health Concern
10. Pre-Clinical Study Suggests How Steroid Can Reverse Post-Traumatic Stress
11. Insight Into Tanning Process Suggests Novel Way to Prevent Skin Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 2The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 3The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 4The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 5Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 2Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 3Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program 2Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program 3Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin An Investigational Treatment for Type 2 Diabetes 4914 1Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin An Investigational Treatment for Type 2 Diabetes 4914 2Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin An Investigational Treatment for Type 2 Diabetes 4914 3IBM Scientists First to Image the Anatomy of a Molecule 4913 1IBM Scientists First to Image the Anatomy of a Molecule 4913 2IBM Scientists First to Image the Anatomy of a Molecule 4913 3IBM Scientists First to Image the Anatomy of a Molecule 4913 4IBM Scientists First to Image the Anatomy of a Molecule 4913 5Four Studies Published in The Lancet Show roflumilast 28Daxas 28R 29 29 a New Oral Approach to COPD Improves Lung Function and Reduces Exacerbation 4911 1Four Studies Published in The Lancet Show roflumilast 28Daxas 28R 29 29 a New Oral Approach to COPD Improves Lung Function and Reduces Exacerbation 4911 2Four Studies Published in The Lancet Show roflumilast 28Daxas 28R 29 29 a New Oral Approach to COPD Improves Lung Function and Reduces Exacerbation 4911 3Four Studies Published in The Lancet Show roflumilast 28Daxas 28R 29 29 a New Oral Approach to COPD Improves Lung Function and Reduces Exacerbation 4911 4Four Studies Published in The Lancet Show roflumilast 28Daxas 28R 29 29 a New Oral Approach to COPD Improves Lung Function and Reduces Exacerbation 4911 5Four Studies Published in The Lancet Show roflumilast 28Daxas 28R 29 29 a New Oral Approach to COPD Improves Lung Function and Reduces Exacerbation 4911 6Four Studies Published in The Lancet Show roflumilast 28Daxas 28R 29 29 a New Oral Approach to COPD Improves Lung Function and Reduces Exacerbation 4911 7Four Studies Published in The Lancet Show roflumilast 28Daxas 28R 29 29 a New Oral Approach to COPD Improves Lung Function and Reduces Exacerbation 4911 8Four Studies Published in The Lancet Show roflumilast 28Daxas 28R 29 29 a New Oral Approach to COPD Improves Lung Function and Reduces Exacerbation 4911 9